Torrent Pharma - Visualising A Deal With Cipla; Key Positives, Negatives: Yes Securities Analysis

BQ Prime’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BQ Prime’s subscribers an opportunity to expand their understanding of companies, sectors and the economy..Yes Securities Report.We assess the contours of recently speculated deal in the media about Torrent Pharmaceuticals Ltd.’s acquisition of Cipla Ltd.’s promoter stake. While the deal is hypothetical at this juncture, we attempt to flag off the key positives/negatives and what it means for Torrent. Upfront, deal would require large capital outlay to buy out promoter stake followed by an open offer. In order to keep debt/Ebitda of combined entity manageable to say around ~three-four times, Torrent Pharma may have to resort to large equity dilution which may be to extent of 40-50%. Scale of the deal would overshadow Sun Pharmaceutical Industries Ltd.'s acquisition of Ranbaxy (even as Ranbaxy was ~60% of Sun’s sales) and would upend the domestic pharma pecking order with combined entity owning ~35 brands each more than Rs 1 billion. Operationally, Cipla and Torrent have complementary presence with not much overlap; albeit it would also bring a larger U.S. business into Torrent’s fold, a not so keen geography for its management.Notwithstanding domestic synergies, sheer size of integration and need to rationalize would compound on top of our debt and return on capital employed dilution concerns. While we take this opportunity to roll over to FY25 and raise rating to 'Add' as we bump up estimates after Q1 FY24 results, clearly our stance is hinged on Torrent as a standalone entity; any deal with Cipla would bring lot of uncertainty around execution, debt and ROCE dilution..Click on the attachment to read the full report:.Indoco Remedies - Resolution Of Facilities A Key Monitorable: Nirmal Bang.DISCLAIMERThis report is authored by an external party. BQ Prime does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BQ Prime..Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

Torrent Pharma - Visualising A Deal With Cipla; Key Positives, Negatives: Yes Securities Analysis

Upfront, deal would require large capital outlay to buy out promoter stake followed by an open offer.

NDTV Profit

NDTV Profit

Follow Us

DISCOVER US FASTER

DOWNLOAD THE APP